Prima facie evidence that ceo's do not belong on a company's board of directors due the inherent conflict of interest between shareholder's interests and their own. And/or that 85.5% of them are overpaid.
<<Termeer also would get a cash change-in-control payment of $11 million. So he would pocket $29 million if Genzyme accepts the $69-a-share offer. However, he would lose $38 million in the present value of three year’s future pay and so would end up $9 million in the hole.>>